Clinical Rheumatology

Springer

The use of low-dose naltrexone (LDN) as a novel anti-inflammatory treatment for chronic pain

 

Jarred Younger, Luke Parkitny, and David McLain

 

Additional article information

 

Abstract

 

Low-dose naltrexone (LDN) has been demonstrated to reduce symptom severity in conditions such as fibromyalgia, Crohn’s disease, multiple sclerosis, and complex regional pain syndrome. We review the evidence that LDN may operate as a novel anti-inflammatory agent in the central nervous system, via action on microglial cells. These effects may be unique to low dosages of naltrexone and appear to be entirely independent from naltrexone’s better-known activity on opioid receptors. As a daily oral therapy, LDN is inexpensive and well-tolerated. Despite initial promise of efficacy, the use of LDN for chronic disorders is still highly experimental. Published trials have low sample sizes, and few replications have been performed. We cover the typical usage of LDN in clinical trials, caveats to using the medication, and recommendations for future research and clinical work. LDN may represent one of the first glial cell modulators to be used for the management of chronic pain disorders.

  • Twitter - Grey Circle
  • Facebook - Grey Circle
  • Instagram - Grey Circle

© 2019 BY SOHO Integrative Medicine All Rights Reserved

5301 Office Park Dr  Suite 400 Bakersfield  CA  93309